Disease‐modifying antirheumatic drugs
Identifieur interne : 000C49 ( Main/Exploration ); précédent : 000C48; suivant : 000C50Disease‐modifying antirheumatic drugs
Auteurs : Vera J. Stecher [États-Unis] ; John A. Carlson [États-Unis] ; Kevin M. Connolly [États-Unis] ; Denis M. Bailey [États-Unis]Source :
- Medicinal Research Reviews [ 0198-6325 ] ; 1985-07.
English descriptors
- Teeft :
- Acylator phenotype, Adverse effects, Amer, American association, Antibody production, Antimalarial, Antirheumatic, Antirheumatic drugs, Arthritic rats, Arthritis, Arthritis rheum, Autoimmune disease, Bailey, Biochemical variables, Blood cells, Cancer patients, Carlson, Cell antibody production, Cell number, Cell response, Chloroquine, Clin, Clinical improvement, Clinical trials, Clinical variables, Clinics committee, Connolly, Control group, Cotton pellet granuloma, Crockson, Daily dose, Disease remission, Dmard, Dmard therapy, Dmards, Drug therapy, Drug treatment, Early stages, Effector, Effector cell function, Effector cells, Erythrocyte sedimentation rate, Experimental diet, Experimental group, Gold salts, Goldstein, Greater benefit, Haptene formation, Helper, Helper cell function, Helper cell proliferation, Helper cells, High incidence, High levels, Human model, Hydroxychloroquine, Ideal drug, Immune, Immune dysfunction, Immune response, Immune system, Immunol, Immunological, Immunological dysfunction, Immunomodulating activity, Immunomodulating drug therapy, Immunomodulatory activity, Inflammation, Inflammation research, Injectable gold, Joint destruction, Large numbers, Lupus erythematosus, Lymphocyte, Macrophage, Mcconkey, Medicinal chemistry, Normal host, Normal levels, Nsaid, Nutritional therapy, Patient populations, Percent gold, Peripheral blood, Peripheral blood leukocytes, Possible mechanisms, Previous examples, Proc, Prostaglandin, Raven press, Research institute, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatol, Risk ratio, Scand, Side effects, Significant decrease, Splenic lymphocytes, Stecher, Sulphasalazine, Suppl, Suppressor, Suppressor cell, Suppressor cell proliferation, Suppressor cells, Suppressor response, Symptomatic relief, Therapeutic agent.
Url:
DOI: 10.1002/med.2610050305
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000D58
- to stream Istex, to step Curation: 000D57
- to stream Istex, to step Checkpoint: 000925
- to stream Main, to step Merge: 000C63
- to stream Main, to step Curation: 000C49
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disease‐modifying antirheumatic drugs</title><author><name sortKey="Stecher, Vera J" sort="Stecher, Vera J" uniqKey="Stecher V" first="Vera J." last="Stecher">Vera J. Stecher</name></author><author><name sortKey="Carlson, John A" sort="Carlson, John A" uniqKey="Carlson J" first="John A." last="Carlson">John A. Carlson</name></author><author><name sortKey="Connolly, Kevin M" sort="Connolly, Kevin M" uniqKey="Connolly K" first="Kevin M." last="Connolly">Kevin M. Connolly</name></author><author><name sortKey="Bailey, Denis M" sort="Bailey, Denis M" uniqKey="Bailey D" first="Denis M." last="Bailey">Denis M. Bailey</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1A3F5E9D74FA16125C32AD312F886727A964F8D4</idno><date when="1985" year="1985">1985</date><idno type="doi">10.1002/med.2610050305</idno><idno type="url">https://api.istex.fr/document/1A3F5E9D74FA16125C32AD312F886727A964F8D4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D58</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D58</idno><idno type="wicri:Area/Istex/Curation">000D57</idno><idno type="wicri:Area/Istex/Checkpoint">000925</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000925</idno><idno type="wicri:doubleKey">0198-6325:1985:Stecher V:disease:modifying:antirheumatic</idno><idno type="wicri:Area/Main/Merge">000C63</idno><idno type="wicri:Area/Main/Curation">000C49</idno><idno type="wicri:Area/Main/Exploration">000C49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Disease‐modifying antirheumatic drugs</title><author><name sortKey="Stecher, Vera J" sort="Stecher, Vera J" uniqKey="Stecher V" first="Vera J." last="Stecher">Vera J. Stecher</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Sterling‐Winthrop Research Institute, Rensselaer</wicri:cityArea></affiliation></author><author><name sortKey="Carlson, John A" sort="Carlson, John A" uniqKey="Carlson J" first="John A." last="Carlson">John A. Carlson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Sterling‐Winthrop Research Institute, Rensselaer</wicri:cityArea></affiliation></author><author><name sortKey="Connolly, Kevin M" sort="Connolly, Kevin M" uniqKey="Connolly K" first="Kevin M." last="Connolly">Kevin M. Connolly</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Sterling‐Winthrop Research Institute, Rensselaer</wicri:cityArea></affiliation></author><author><name sortKey="Bailey, Denis M" sort="Bailey, Denis M" uniqKey="Bailey D" first="Denis M." last="Bailey">Denis M. Bailey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Sterling‐Winthrop Research Institute, Rensselaer</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Medicinal Research Reviews</title><title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title><idno type="ISSN">0198-6325</idno><idno type="eISSN">1098-1128</idno><imprint><biblScope unit="vol">5</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="371">371</biblScope><biblScope unit="page" to="390">390</biblScope><biblScope unit="page-count">20</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1985-07">1985-07</date></imprint><idno type="ISSN">0198-6325</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0198-6325</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acylator phenotype</term><term>Adverse effects</term><term>Amer</term><term>American association</term><term>Antibody production</term><term>Antimalarial</term><term>Antirheumatic</term><term>Antirheumatic drugs</term><term>Arthritic rats</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune disease</term><term>Bailey</term><term>Biochemical variables</term><term>Blood cells</term><term>Cancer patients</term><term>Carlson</term><term>Cell antibody production</term><term>Cell number</term><term>Cell response</term><term>Chloroquine</term><term>Clin</term><term>Clinical improvement</term><term>Clinical trials</term><term>Clinical variables</term><term>Clinics committee</term><term>Connolly</term><term>Control group</term><term>Cotton pellet granuloma</term><term>Crockson</term><term>Daily dose</term><term>Disease remission</term><term>Dmard</term><term>Dmard therapy</term><term>Dmards</term><term>Drug therapy</term><term>Drug treatment</term><term>Early stages</term><term>Effector</term><term>Effector cell function</term><term>Effector cells</term><term>Erythrocyte sedimentation rate</term><term>Experimental diet</term><term>Experimental group</term><term>Gold salts</term><term>Goldstein</term><term>Greater benefit</term><term>Haptene formation</term><term>Helper</term><term>Helper cell function</term><term>Helper cell proliferation</term><term>Helper cells</term><term>High incidence</term><term>High levels</term><term>Human model</term><term>Hydroxychloroquine</term><term>Ideal drug</term><term>Immune</term><term>Immune dysfunction</term><term>Immune response</term><term>Immune system</term><term>Immunol</term><term>Immunological</term><term>Immunological dysfunction</term><term>Immunomodulating activity</term><term>Immunomodulating drug therapy</term><term>Immunomodulatory activity</term><term>Inflammation</term><term>Inflammation research</term><term>Injectable gold</term><term>Joint destruction</term><term>Large numbers</term><term>Lupus erythematosus</term><term>Lymphocyte</term><term>Macrophage</term><term>Mcconkey</term><term>Medicinal chemistry</term><term>Normal host</term><term>Normal levels</term><term>Nsaid</term><term>Nutritional therapy</term><term>Patient populations</term><term>Percent gold</term><term>Peripheral blood</term><term>Peripheral blood leukocytes</term><term>Possible mechanisms</term><term>Previous examples</term><term>Proc</term><term>Prostaglandin</term><term>Raven press</term><term>Research institute</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Risk ratio</term><term>Scand</term><term>Side effects</term><term>Significant decrease</term><term>Splenic lymphocytes</term><term>Stecher</term><term>Sulphasalazine</term><term>Suppl</term><term>Suppressor</term><term>Suppressor cell</term><term>Suppressor cell proliferation</term><term>Suppressor cells</term><term>Suppressor response</term><term>Symptomatic relief</term><term>Therapeutic agent</term></keywords></textClass></profileDesc></teiHeader></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Stecher, Vera J" sort="Stecher, Vera J" uniqKey="Stecher V" first="Vera J." last="Stecher">Vera J. Stecher</name></region><name sortKey="Bailey, Denis M" sort="Bailey, Denis M" uniqKey="Bailey D" first="Denis M." last="Bailey">Denis M. Bailey</name><name sortKey="Carlson, John A" sort="Carlson, John A" uniqKey="Carlson J" first="John A." last="Carlson">John A. Carlson</name><name sortKey="Connolly, Kevin M" sort="Connolly, Kevin M" uniqKey="Connolly K" first="Kevin M." last="Connolly">Kevin M. Connolly</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1A3F5E9D74FA16125C32AD312F886727A964F8D4
|texte= Disease‐modifying antirheumatic drugs
}}
| This area was generated with Dilib version V0.6.33. |  |